Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02534649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

Study acronym: BIP
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 2 of 3 entries
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv9
  3. Study sites: 6 to 7v8
  4. Enrollment target: 2000 to 10000v7 Show 4 more changesShow less
    • Primary completion date: Mar 2025 to Mar 2028
    • Study sites: 4 to 6
    • Study completion date: Dec 2025 to Dec 2029
    • Eligibility criteria shortened, about 141 words
  5. Primary completion date: Mar 2020 to Mar 2025
    • Study sites: 2 to 4
    • Study completion date: Dec 2022 to Dec 2025
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date: Dec 2018 to Mar 2020
    • Study sites: 1 to 2
    • Study completion date: Dec 2019 to Dec 2022
    • Eligibility criteria shortened, about 111 words
    v5
  2. Study completion date: Dec 2019v4
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.
Trial Details
NCT Number NCT02534649
Lead Sponsor Institut Bergonié
Conditions
(from sponsor)		 Solid Tumor, Hematological Malignancy
Related terms Hematologic Neoplasms
Enrollment 10,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov